Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMD-477 in Type 1 Diabetes
NCT04779645Phase 2Active, not recruiting
- Sponsor
- University of California, San Diego
- Start
- Jul 2021
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of volagidemab in type 1 diabetes mellitus (T1D), sponsored by University of California, San Diego. Started Jul 2021; status: active, not recruiting.
02
Drugs
volagidemab
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04779645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04779645.